drugset / Trial / NCT07584434
A Phase 1, First-in-human Study of VX-433
RandomizedSequentialQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Timeline
- Start
- 2026-05-21
- Primary completion
- 2027-03-05
- Completion
- 2027-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bupropion | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | VX-433 | Unknown | — | Oral |